AFT Pharmaceuticals today announces an Agreement with Hikma Pharmaceuticals USA to distribute its patented1 COMBOGESIC® Tablets, a fixed dose combination (FDC) (acetaminophen and ibuprofen), non-opioid analgesia in a single tablet for adult pain management to select markets in the United States, the largest pharma market in the world.2The Agreement furthers the cooperation between the companies after the 21 April 2021 agreement between AFT and Hikma for the intravenous form, COMBOGESIC® IV, and will cover market segments where the IV dose form will be used such as hospitals and ambulatory surgical centres.AFT Managing Director Dr Hartley Atkinson said: “COMBOGESIC® IV was launched by Hikma in February this year and we believe that the addition of the oral dose form, COMBOGESIC® Tablets will assist uptake of the IV dose form in addition to sales of the tablet.

AFT Pharmaceuticals今天宣布与美国希克玛制药公司（Hikma Pharmaceuticals USA）达成协议，将其专利的1种固定剂量组合（FDC）（对乙酰氨基酚和布洛芬）非阿片类镇痛药在单一片剂中用于成人疼痛管理，以在美国选择市场。美国是世界上最大的制药市场。2该协议在2021年4月21日AFT和Hikma就静脉注射形式COMBOGESIC®IV达成协议后，进一步促进了两家公司之间的合作，并将涵盖将使用IV剂量形式的细分市场，如医院和门诊手术中心。AFT董事总经理哈特利·阿特金森博士表示：“COMBOGESIC®IV于今年2月由Hikma推出，我们相信，除了片剂的销售之外，口服剂型COMBOGESIC®片剂的加入将有助于吸收IV剂型。

As previously indicated, we are planning to see tablet sales start during this calendar year. AFT will benefit from the agreement by means of a profit share.Hikma is a global pharmaceutical company focused on complex and differentiated generic and branded generic pharmaceuticals across a broad range of indications, including respiratory, oncology and pain management.It is the third largest US supplier of generic injectable medicines by volume3, and a trusted, reliable partner and dependable source of over 760 high-quality generic, specialty, and branded pharmaceutical products that hospitals, physicians, and pharmacists need to treat their patients.Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial Officer.For more information:InvestorsDr Hartley AtkinsonManaging DirectorAFT PharmaceuticalsTel: +64 9488 0232MediaRichard InderThe ProjectTel: +64 21 645 643 Source: aftpharm.co.

如前所述，我们计划在本日历年开始平板电脑销售。AFT将通过利润分成的方式从协议中受益。Hikma是一家全球性制药公司，专注于复杂和差异化的仿制药和品牌仿制药，涵盖广泛的适应症，包括呼吸系统，肿瘤学和疼痛管理。它是美国第三大仿制药注射剂供应商，也是值得信赖、可靠的合作伙伴和可靠的来源，拥有医院、医生和药剂师治疗患者所需的760多种优质仿制药、专业药品和品牌药品。首席财务官马尔科姆·塔比代表AFT制药有限公司发布。欲了解更多信息，请咨询投资方Hartley Atkinson博士管理董事Aft PharmaceuticalsTel：+64 9488 0232 MediaRichard Inderth项目电话：+64 21 645 643来源：aftpharm.co。